AXSM
Axsome Therapeutics, Inc.
AXSM lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
AXSM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AXSM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
AXSM PE Valuation
AXSM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 83x next year's earnings.
AXSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AXSM to return to profit, with revenue growing. However, they disagree widely on these estimates.
AXSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.74 | — |
| Q3 2026 | -$3.05 | +$1.62 |
| Q2 2026 | -$3.74 | +$1.33 |
| Q1 2026 | -$3.72 | +$2.05 |
| Q4 2025 | -$3.68 | +$2.31 |
| Q3 2025 | -$4.67 | +$1.93 |
| Q2 2025 | -$5.07 | +$1.51 |
| Q1 2025 | -$5.77 | +$0.68 |
| Q4 2024 | -$5.99 | -$0.72 |
AXSM is still losing money, but far less than before: $3.05 per share over the past year, against $6.60 at its worst in late 2024.
AXSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.7M | +52% |
| Q2 2026 | $218.4M | +46% |
| Q1 2026 | $191.2M | +57% |
| Q4 2025 | $196M | +65% |
| Q3 2025 | $171M | +63% |
| Q2 2025 | $150M | +72% |
| Q1 2025 | $121.5M | +62% |
| Q4 2024 | $118.8M | +66% |
AXSM's revenue has grown year over year for 10 quarters in a row: $260M last quarter, up 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.3% | +23 points |
| Q2 2026 | -23% | +1.7 points |
| Q1 2026 | -33% | +14 points |
| Q4 2025 | -14% | +47 points |
| Q3 2025 | -27% | +33 points |
| Q2 2025 | -24% | +65 points |
| Q1 2025 | -47% | +43 points |
| Q4 2024 | -61% | +76 points |
AXSM's operating margin was −4.3% last quarter, up 23 points from the same quarter a year ago, near the top of its range since 2022.
AXSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -1078% |
| Q2 2026 | -$33.4M | -$966K |
| Q1 2026 | -$20.8M | +$22.9M |
| Q4 2025 | -$18.7M | +$7.5M |
| Q3 2025 | $988K | +$19.7M |
| Q2 2025 | -$32.4M | -$2.3M |
| Q1 2025 | -$43.7M | +$9.9M |
| Q4 2024 | -$26.2M | +$4.1M |
AXSM has burned cash in almost every quarter: −$83M over the past year, against −$101M the year before.
AXSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +645K shares |
| 1 year | +4.8% | +2.4M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +39% | +14.8M shares |
| Available history | +54% | +18.4M shares |
AXSM has 52M diluted shares, up 4.8% from a year ago.
AXSM Net Leverage
AXSM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AXSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 13.4 | Oversold |
AXSM's weekly RSI is 34 (neutral) and its Stochastic is 13 (oversold).
AXSM PE vs Healthcare Sector
AXSM has no meaningful PE right now: it lost money over the past year.
AXSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.3 | 8.8% below |
| 20 week MA | $195.1 | 26% below |
| 50 week MA | $191.3 | 25% below |
| 100 week MA | $152.4 | 5.3% below |
| 200 week MA | $114.9 | 26% above |
AXSM has fallen below most of its moving averages, though it's still 26% above its 200-week average.
AXSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $102.0 | $84.9 | -17% |
| 2021 | $84.9 | $38.5 | -55% |
| 2022 | $38.5 | $73.8 | +92% |
| 2023 | $73.8 | $79.6 | +7.9% |
| 2024 | $79.6 | $86.7 | +8.9% |
| 2025 | $86.7 | $152.1 | +75% |
| 2026 YTD | $152.1 | $144.4 | -5.1% |
AXSM has finished higher in four of the last six years, two of them by more than 50%. It's down 5.1% so far in 2026.